Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Severe Aplastic Anemia
NCT02828592Phase 2Recruiting
- Sponsor
- Northside Hospital
- Start
- Sep 2016
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in aplastic anemia, sponsored by Northside Hospital. Primary endpoint: Sustained engraftment after T-cell replete HLA-mismatched haploidentical bone marrow transplantation at 2 years. Started Sep 2016; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT02828592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828592.